SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...
Please provide your email address to receive an email when new articles are posted on . Published results showed integration of fracture liaison and orthopedic services, as well as inpatient ...
Treatment with zoledronic acid (Zometa) before onset of skeletal morbidity may lower the risk of skeletal-related events (SRE) and prolong the time to the first SRE in men with bone metastases from ...
Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.
The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...
Risk factors and predictors of tumor recurrence among breast cancer patients in a tertiary government hospital in the Philippines. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global ...
GLASGOW, Scotland – A single infusion of zoledronic acid (Aclasta) prevents bone turnover in people at risk of Paget’s disease in an analysis of data from the Zoledronate in the Prevention of Paget’s ...
Renal outcomes did not differ between patients with hip fracture and CKD who did vs did not receive low-dose zoledronic acid, except for a change in serum calcium levels. Low-dose inpatient zoledronic ...
One annual infusion of zoledronic acid (Reclast) significantly reduces fracture risk in postmenopausal women with osteoporosis, according to results of a major trial. An international group of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results